Understand the source comparison
FPF 1070: Research-Grade Peptide Comparison
This table compares FPF 1070 against structurally related peptides commonly used in metabolic research. Understanding these differences helps researchers select the appropriate compound for specific experimental designs. FPF 1070 Presumed incretin receptor ago
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares FPF 1070 against structurally related peptides commonly used in metabolic research. Understanding these differences helps researchers select the appropriate compound for specific experimental designs.
- FPF 1070
- Presumed incretin receptor agonist (GLP-1 or dual GLP-1/GIP)
- Unknown—requires supplier clarification
- Unknown—sequence-dependent
- Non-standardized nomenclature; structural identity requires verification
- Use only if supplier provides full amino acid sequence and purity documentation—otherwise reproducibility cannot be guaranteed
- Semaglutide
- Selective GLP-1 receptor agonist
- ~7 days (168 hours)
- 0.1–1.0 mg/kg weekly in rodent models
- FDA-approved human therapeutic (Ozempic, Wegovy)—extensive published data
- Gold standard for GLP-1 pathway research; well-characterized pharmacokinetics and metabolic endpoints
- Tirzepatide
- Dual GLP-1/GIP receptor agonist
- ~5 days (120 hours)
- 0.5–2.0 mg/kg weekly in rodent models
- Superior weight reduction vs GLP-1 monotherapy in SURPASS trials (15.7% vs 10.5% at 40 weeks)
- Best choice for studies comparing single vs dual incretin agonism; published dose-response data available
- Liraglutide
- ~13 hours
- 0.2–0.8 mg/kg daily in rodent models
- Shorter half-life than semaglutide—requires daily dosing but faster washout for acute studies
- Ideal for short-term mechanistic studies where rapid clearance is advantageous
- Exenatide
- Selective GLP-1 receptor agonist (exendin-4 derivative)
- ~2.4 hours (immediate-release)
- 1–10 μg/kg twice daily in rodent models
- First-generation GLP-1 agonist—shorter duration but structurally distinct from human GLP-1
- Useful for receptor selectivity studies; structurally based on Gila monster peptide (exendin-4) rather than human GLP-1